Connectome, a neurotechnology startup, has raised approximately €1.7 million ($2 million) in a pre-seed funding round to advance its platform for personalised brain health monitoring.
The round was led by Redstone, with participation from Concept Ventures, Octopus, and a group of strategic investors and angels across Europe and the United States. The funding also includes €103.6k ($120k) in non-dilutive public support. The capital will be used to further develop the company’s technology and support early product deployment.
What The Company Does
Founded in 2024, Connectome focuses on improving how cognitive health is measured and understood by providing continuous, personalised insights into brain function. Its platform tracks changes in brain activity over time, linking them to factors such as lifestyle, environment, and overall health.
Rather than relying on one-time assessments, the system builds longitudinal profiles of brain function, enabling a more accurate understanding of how cognitive performance evolves in real-world conditions. The technology is based on research from Imperial College London and identifies measurable patterns in everyday behaviour and neural activity.
By combining brain-related data with contextual inputs such as sleep and physical activity, Connectome aims to deliver a more comprehensive and individualised view of cognitive health.
Advertisement
Market Context / Industry Background
Advances in wearable technology and digital health have improved the monitoring of physical health metrics, but similar progress in brain health has been more limited. At the same time, there is increasing awareness of cognitive challenges such as burnout, attention deficits, and memory decline, particularly among younger populations. These trends are contributing to a broader recognition of cognitive health as a key component of overall wellbeing.
This gap is driving interest in tools that can provide continuous, real-world insights into brain function. Early detection and monitoring are particularly relevant for conditions such as ADHD and dementia, where timely intervention can improve outcomes. In addition, ongoing monitoring may help identify patterns or changes in cognitive performance over time, supporting more consistent evaluation across different contexts and environments, as well as across different stages of life.
Neurotechnology platforms that integrate behavioural, physiological, and contextual data are emerging as a potential solution, enabling more personalised and preventative approaches to cognitive health. Such platforms aim to support a more holistic understanding of brain function by combining multiple data sources and facilitating longitudinal observation in everyday contexts. This approach may also contribute to more informed interactions between users and healthcare professionals over time, supporting better communication and shared decision-making processes.
Founder / Investor Commentary
Lucas Scherdel, CEO of Connectome, highlighted the gap between advances in physical health monitoring and the limited tools available for understanding brain function. He noted that cognitive health plays a central role in how individuals work, interact, and age, yet remains insufficiently measured.
He emphasised that Connectome’s approach focuses on longitudinal measurement, enabling the creation of personalised models of brain function that could inform both everyday wellbeing and future clinical applications.
Growth Plans / Use Of Funds
The newly raised funding will be used to launch the platform with selected partners and continue research efforts to expand its capabilities. This includes advancing studies such as the LUCIID study, which explores how repeated measurements can define individual cognitive baselines and improve interpretation of changes over time.
The company also plans to broaden its application areas beyond lifestyle and wearable integrations, with potential expansion into clinical and enterprise use cases.
About Connectome
Connectome is a neurotechnology company developing tools for personalised brain health monitoring. Founded in 2024. Headquartered in Zurich and London. The company focuses on tracking cognitive function over time to provide data-driven insights that support wellbeing, early detection, and long-term brain health.
